Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Stress Levels Periodontitis and Metabolic Syndrome

11 de noviembre de 2026 actualizado por: Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital

Evaluation of Salivary Cortisol, Dehydroepiandrosterone, Chromogranin A, and Psychological Stress Levels in Patients With Periodontitis and Metabolic Syndrome

The purpose of this observational study is to evaluate the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A, as well as the levels of psychological stress, in patients with periodontitis and/or metabolic syndrome. The primary research question the study aims to address is:

- Are the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A and psychological stress in patients with periodontitis and/or metabolic syndrome associated with their periodontal status and metabolic syndrome?

Participants-categorized into a control group, those with periodontitis only, those with metabolic syndrome only, and those with both periodontitis and metabolic syndrome-will undergo a clinical periodontal examination, provide saliva samples for the assessment of cortisol, dehydroepiandrosterone, and chromogranin A levels, and complete validated scales designed to measure psychological stress. The findings will help clarify the relationship between psychological stress, stress-related salivary biomarkers, metabolic syndrome, and periodontal health.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

Within the scope of the study, the Rosenberg Self-Esteem Scale and the Social Appearance Anxiety Scale will be administered. Salivary markers-cortisol, dehydroepiandrosterone, and chromogranin A-will be analyzed using the ELISA method. Periodontal clinical parameters (plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment loss) will be measured.

Tipo de estudio

De observación

Inscripción (Estimado)

100

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Oguz KOSE, Professor Dr.
  • Número de teléfono: +90 541 348 64 65
  • Correo electrónico: oguz.kose@erdogan.edu.tr

Ubicaciones de estudio

    • Rize Province
      • Rize, Rize Province, Turquía (Türkiye), 53020
        • Department of Periodontology of the Faculty of Dentistry of Recep Tayyip Erdogan University
        • Contacto:
          • RTEU Faculty of Dentistry, Department of Periodontology
          • Número de teléfono: +90 464 222 00 00
          • Correo electrónico: dis@erdogan.edu.tr

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Individuals who presented to the Internal Medicine Outpatient Clinic at the Recep Tayyip Erdoğan University Faculty of Medicine Training and Research Hospital and met the diagnostic criteria for metabolic syndrome as defined by the American Diabetes Association (ADA) or the International Diabetes Federation (IDF); healthy volunteers who presented to the Periodontology Clinic at the Recep Tayyip Erdoğan University Faculty of Dentistry; and individuals who were diagnosed with periodontitis but did not meet the criteria for metabolic syndrome.

Descripción

Inclusion Criteria:

  • Individuals between the ages of 18 and 65,
  • Those who have at least 20 natural teeth,
  • Individuals who have provided written informed consent for participation in the research
  • Individuals diagnosed with periodontitis and/or metabolic syndrome

Exclusion Criteria:

  • Individuals who have received periodontal treatment (surgical or non-surgical) within the last 6 months,
  • Individuals with a history of using antibiotics, anti-inflammatory drugs, or immunosuppressive medications within the last 3 months,
  • Individuals with a history of systemic disease who do not meet the criteria for metabolic syndrome (e.g., malignancy, autoimmune diseases, liver/kidney failure),
  • Individuals who have been diagnosed with a psychiatric disorder or are undergoing regular psychiatric treatment,
  • Pregnant or breastfeeding women,
  • Individuals with physical or mental disabilities that prevent them from maintaining their oral hygiene.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Healthy Control Group

Individuals with no clinical or radiographic signs of periodontal disease and no history of systemic disease

Periodontitis Group (Systemically Healthy)

Individuals diagnosed with periodontitis according to the 2018 American Academy of Periodontology classification, but with no history of systemic disease

Metabolic Syndrome Group (Periodontally Healthy)

Individuals diagnosed with metabolic syndrome according to American Diabetes Association or International Diabetes Federation criteria, but without periodontitis

Periodontitis + Metabolic Syndrome Group

Individuals diagnosed with both metabolic syndrome and periodontitis

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Plaque Index
Periodo de tiempo: Day 1

Plaque Index (PI) (Silness and Löe, 1964) This index is used to evaluate the amount of dental plaque accumulation on tooth surfaces. Each tooth's four surfaces (buccal, lingual, mesial, distal) are examined using a probe or visually. Each surface is scored from 0 to 3. The average score is calculated for each tooth. The overall plaque index is obtained by averaging the scores from all examined teeth.

Score Description

0 No plaque.

  1. No visible plaque, but a slight film of plaque is detected when a probe is run along the gingival margin.
  2. Visible plaque along the gingival margin, forming a continuous band.
  3. Abundant plaque covering the gingival area and extending toward the middle of the tooth surface, including the interproximal spaces.
Day 1
Gingival Index
Periodo de tiempo: Day 1

The Gingival Index is used to assess the presence and severity of gingival inflammation (gingivitis). Four surfaces of each tooth (buccal, lingual, mesial, distal) are examined visually and with a periodontal probe. The evaluation considers color changes, edema (swelling), tissue consistency, and bleeding on probing. Each surface is scored from 0 to 3. The average score per tooth is calculated, and then the overall average is used to determine the individual's GI score.

Score Description

0 Healthy gingiva: normal color and texture, no bleeding

  1. Mild inflammation: slight color change and swelling, no bleeding on probing
  2. Moderate inflammation: redness, edema, soft tissue, bleeding on probing
  3. Severe inflammation: marked redness and swelling, ulceration, possible spontaneous bleeding
Day 1
Bleeding on Probing Index
Periodo de tiempo: Day 1

This index is used to assess the presence and severity of gingival inflammation by observing bleeding after gentle pressure is applied to the gingival sulcus using a periodontal probe. A thin periodontal probe is gently inserted into the gingival sulcus with light pressure (approximately 20-25 grams). Bleeding occurring within 10-30 seconds is observed. Each measurement site is recorded as either "bleeding present" or "bleeding absent." Presence of bleeding is an early and sensitive indicator of gingival inflammation.

Score Description: 0 No bleeding 1 Bleeding present (mild or severe)

Day 1
Probing Pocket Depth
Periodo de tiempo: Day 1

Using a Williams periodontal probe, the distance between the gingival margin and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Measurement Interpretation

1-3 mm Healthy sulcus

4-5 mm Shallow to moderate pocket

≥6 mm Deep periodontal pocket (advanced disease)

Day 1
Clinical Attachment Loss
Periodo de tiempo: Day 1

Using a Williams periodontal probe, the distance between the enamel-cementum junction and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Clinical Attachment Loss Value Interpretation

0-1 mm Healthy / minimal loss

2-3 mm Mild attachment loss

4-5 mm Moderate attachment loss

≥6 mm Severe attachment loss

Day 1
Collection of Saliva Samples
Periodo de tiempo: Day 2

Prior to saliva collection, participants will be instructed to abstain from caffeine and/or nicotine for at least 4 hours and alcohol for at least 24 hours. Saliva will be collected between 9:00 AM and 11:00 AM to minimize circadian variations. Unstimulated saliva flow rate will be collected over 10 minutes using the spitting method and will be expressed in mL/min.

Day 2

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Rosenberg Self-Esteem Scale Score
Periodo de tiempo: Day 1

A four-point scale will be used to score responses to the 10 items. Positive questions are scored as 3: Strongly agree; 2: Agree; 1: Disagree; and 0: Strongly disagree, while negative questions are scored as 0: Strongly agree; 1: Agree; 2: Disagree; and 3: Strongly disagree. According to the final total score of the Rosenberg Self-Esteem Scale scores between 0-15, 15-25, and 25-30 indicate low, normal, and high self-esteem levels, respectively.

Day 1
Social Appearance Anxiety Scale Score
Periodo de tiempo: Day 1

Social Appearance Anxiety Scale 16-item scale concerns how patients feel about their appearance. A score of 1 to 5 is given for each item as follows: 1, completely disagree; 2, partially disagree; 3, unsure; 4, partially agree; 5, I completely agree. Scores range from 16 to 80, with higher scores representing greater social appearance anxiety.

Day 1
Concentration of Cortisol, Dehydroepiandrosterone and Chromogranin A
Periodo de tiempo: approximately in the 4th month

Salivary cortisol, Dehydroepiandrosterone and Chromogranin A will be obtained from unstimulated whole saliva samples. Saliva samples will be stored at -20°C until analyzed. Human salivary cortisol, Dehydroepiandrosterone, and Chromogranin A will be measured using radioenzyme immunoassay using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

approximately in the 4th month

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de noviembre de 2026

Finalización primaria (Estimado)

15 de marzo de 2027

Finalización del estudio (Estimado)

19 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Salivary Stress-MetS-Perio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .